West Pharmaceutical Services, Inc. (WST) Fair Value 2026

WST · Medical Instruments & Supplies ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

8.7 /10

32 fundamental signals · 10 models active

Value Trap Risk

SAFE (15/100)

Quick Summary — As of 2026-08-27, West Pharmaceutical Services, Inc. (WST) trades at $346.09, versus a $110.93 median fair value across its 10 active models — 67.9% below the current price. QOC: 8.7/10. Value Trap Risk: 15/100 (SAFE). 10/13 models active. Within that set, the Bayesian DCF component alone returns $105.90.

Key Facts

Ticker
WST
Price
$346.09
Quality Score
8.7/10
Value Trap Risk
15/100
Models Active
10/13
Last Updated
Strength: Quality Score of 8.7/10 indicates strong fundamentals
Risk: Majority of models suggest overvaluation

Is West Pharmaceutical Services, Inc. (WST) Undervalued or Overvalued in 2026?

According to CirclFi’s 10-model valuation engine, West Pharmaceutical Services, Inc. (WST) appears overvalued as of : the median of 10 independent fair value estimates is $110.93, 67.9% below the current price of $346.09. Estimates range from $33.13 to $303.60. WST scores 8.7/10 on fundamental quality and 15/100 on value-trap risk.

For context, the median US equity CirclFi rates trades at an implied -23.7% versus its own 13-model consensus, across 3,801 rated companies as of 2026-08-27. WST’s -67.9% gap is wider than that market norm, and the Medical Instruments & Supplies sector median is -36.1%. Full market index →

This verdict compares price to intrinsic value only — it is not a buy or sell rating. For the decision case (bull vs bear arguments, risk factors, peers), read Should You Buy West Pharmaceutical Services, Inc. Stock in 2026? →

What Fair Value Does Each Model Give WST?

10 Intrinsic Value Models vs. Current Price ($346.09)

Core Models (Unlocked)
Model Fair Value Upside
Intrinsic · High Conviction
 $105.90 -69.4%
Intrinsic · High Conviction
 $82.85 -76.1%
Ensemble · Low Conviction
 $115.96 -66.5%
Scenario · High Conviction
 $281.09 -18.8%
Unlock the Full Matrix

Access 6 additional models including EROIC Spread, Markov DDM, and more.

$1.30 / day

Billed monthly ($39/mo) or annually ($299/yr)

Unlock All 10 Models →

Cancel anytime · No contracts · Instant access

What Is WST's Fair Value Range?

Spread across 10 independent models · $33.13 to $303.60

CirclFi's 10 active models place West Pharmaceutical Services, Inc. (WST) between $33.13 and $303.60 per share, a spread of 244% of the median. The median of that range — $110.93 — is the fair value CirclFi publishes for WST, against a current price of $346.09.

Low · Markov DDMHigh · Regime Cross
$33.13median $110.93$303.60
Where the range comes from
Most bearish modelMarkov DDM$33.13
Most bullish modelRegime Cross-Sectional$303.60
Model agreement0 bullish · 10 bearishwide

A band this wide is itself the finding. When independent methods land far apart, they are reading a business whose value depends heavily on which lens you apply — volatile earnings, heavy reinvestment, or an asset base that cash-flow and asset-based methods score differently. That disagreement is information: it says the choice of method matters more than usual for WST. Treat the median as one reading among several and compare the individual models below before acting.

Every figure above is one model's standalone output on WST, not a CirclFi price target. How each model works →

What Is West Pharmaceutical Services, Inc. (WST) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, West Pharmaceutical Services, Inc.'s intrinsic value is estimated at $110.93. Trading at its current price of $346.09, the valuation engine raises significant caution: 10 of 10 models flag downside risk, projecting a median implied return of -67.9%. Model dispersion is worth noting: Regime Cross targets $303.60 (-12.3%), versus Markov DDM at $33.13 (-90.4%). This +78.2% range highlights the importance of multi-model analysis rather than relying on any single methodology. Among models with highest confidence, Bayesian DCF, EPV lean bearish — adding weight to the bearish side of the thesis.

What Do the Models Say About WST?

10 of 13 models are currently active for WST. All 10 active models suggest the stock trades above fair value. Taken together, their median fair value for WST is $110.93 — the figure CirclFi publishes as this stock's fair value. One component of that median, the Bayesian DCF, returns $105.90 on its own, implying -69.4% downside from the current price. See which stocks rank higher →

How Does WST Rank in Medical Instruments & Supplies?

Among 55 Medical Instruments & Supplies stocks, WST ranks #6 by Quality of Company score. CirclFi's QOC score of 8.7/10 evaluates 32 fundamental signals. A score of 8.7 places WST in the top tier.

See all Most Undervalued Medical Instruments & Supplies Stocks →

West Pharmaceutical Services, Inc. operates in a competitive landscape where fundamental quality metrics are key differentiators for long-term value creation.

Is WST a Value Trap?

CirclFi's Value Trap algorithm assigns WST a score of 15/100 (SAFE). This indicates minimal risk. Fundamentals are healthy. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

10 of 13 models are active for West Pharmaceutical Services, Inc.. Broad coverage provides high confidence. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Quality of Company (QOC) framework, West Pharmaceutical Services, Inc. earns a quality score of 8.7/10. This robust rating reflects the company's standing across 32 fundamental signals spanning profitability, growth consistency, balance sheet strength, and capital allocation efficiency.

The gap between the most bullish and bearish model spans +78.2% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every WST valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across WST's 10 active models, average confidence is 53%. Moderate confidence indicates reasonable fit.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy West Pharmaceutical Services, Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Medical Instruments & Supplies Stocks Should You Also Analyze?

11 related Medical Instruments & Supplies stocks with 13-model coverage

MMSIMerit Medical Systems, Inc.QOC 8.7COOThe Cooper Companies, Inc.QOC 8.5ATRAptarGroup, Inc.QOC 8.9NEPHNephros, Inc.QOC 8.4LMATLeMaitre Vascular, Inc.QOC 9.3ALGNAlign Technology, Inc.QOC 8.4WRBYWarby Parker Inc.QOC 7.6TFXTeleflex IncorporatedQOC 6.2PLSEPulse Biosciences, Inc.QOC 5.3ISRGIntuitive Surgical, Inc.QOC 9.4RMDResMed Inc.QOC 9.4

Read investment analysis: MMSI · COO · ATR · NEPH · LMAT · ALGN · WRBY · TFX · PLSE · ISRG · RMD

Which Other Stocks Have a Similar Quality Score to WST?

7 companies across all industries closest to WST’s Quality of Company score of 8.7/10.

DYDycom Industries, Inc.QOC 8.7HUBSHubSpot, Inc.QOC 8.7WSOWatsco, Inc.QOC 8.7PRIMPrimoris Services CorporationQOC 8.7MCYMercury General CorporationQOC 8.7GLBEGlobal-E Online Ltd.QOC 8.7NVDANVIDIA CorporationQOC 10.0

Read investment analysis: DY · HUBS · WSO · PRIM · MCY · GLBE · NVDA

Where Does WST Sit in CirclFi's Medical Instruments & Supplies Rankings?

WST is ranked against every other Medical Instruments & Supplies stock CirclFi covers in each of these screens.

See all Medical Instruments & Supplies stocks ranked →

What Else Do Investors Ask About West Pharmaceutical Services, Inc.’s Valuation?

What is West Pharmaceutical Services, Inc.'s intrinsic value in 2026?

CirclFi puts West Pharmaceutical Services, Inc. (WST)'s intrinsic value at $110.93 — the median of 10 independent model estimates as of 2026-08-27, ranging from $33.13 to $303.60. One component of that median, the Bayesian DCF, runs 10,000 Monte Carlo simulations with jump-diffusion and returns $105.90 on its own. The Quality of Company score is 8.7/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is WST overvalued or undervalued right now?

At $346.09, 0 of 10 active models suggest WST may be undervalued, while 10 indicate potential overvaluation. The median of all 10 fair value estimates is $110.93, 67.9% below the current price of $346.09 — a consensus view that WST is overvalued. The assessment depends on which methodology best fits West Pharmaceutical Services, Inc.'s business model in Medical Instruments & Supplies.

What does a Quality of Company score of 8.7 mean for WST?

West Pharmaceutical Services, Inc.'s QOC of 8.7/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores above 7 indicate strong fundamentals and disciplined management.

How many valuation models does CirclFi run on WST?

CirclFi analyzes WST with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 10 of 13 are active for this stock. Read the full methodology →

Which valuation models are most bullish and most bearish on WST?

Of the 10 models currently active on WST, Regime Cross-Sectional is the most bullish at $303.60 per share, and Markov DDM is the most bearish at $33.13. CirclFi's published fair value for WST is the median of that range, $110.93, not either extreme. The gap between the two ends equals 244% of the median — a wide spread, meaning the methods genuinely disagree and the median should carry less weight. Browse stocks by value-trap risk →

Is WST a value trap in 2026?

West Pharmaceutical Services, Inc.'s Value Trap score is 15/100 (SAFE). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap.

Cite this analysis — “According to CirclFi’s 10-model valuation engine, West Pharmaceutical Services, Inc. (WST) has a median fair value of $110.93 — 67.9% below the current price of $346.09 — as of 2026-08-27.” Source: circlfi.com/stock/WST/ · Methodology
Primary sources for this WST valuation
  • Financial statements: West Pharmaceutical Services, Inc. 10-K and 10-Q filings on SEC EDGAR (CIK 0000105770) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for WST as of ; valuations recomputed .

You’ve done the research. Don’t stop at half the picture.

Stop collecting opinions. Let 10 mathematical frameworks give you clarity on WST.

Unlock All 10 Fair Values — $39/mo

Cancel anytime · Less than a cup of coffee · Instant access

6 models hidden for WST Unlock All 10 — $39/mo